Stan Musial has joined US pharma company Egalet as chief financial officer having spent the past two years as an independent consultant for start-up businesses.
His most recent in-house role was as chief financial officer at Prism Pharmaceuticals, where he served from 2005 to 2011 before its sale to Baxter Healthcare.
Prior to joining Prism, Musial held the position of VP, finance, and chief financial officer for Strategic Diagnostics.
Egalet is a company that specialises in developing abuse-deterrent medication via a platform that prevents easy extraction and deters abuse of drugs through known routes, such as chewing, snorting, and injecting.
The company’s president and chief executive Bob Radie said: “The addition of Stan to the management team comes at a critical time as the most advanced products in Egalet’s pipeline of abuse-deterrent opioids are nearing phase III.
“Stan’s finance experience will be invaluable as we move our pipeline through development and ultimately to the commercial market.”